Physician profile
Joseph E Barrera
NPI 1629054630
$8,581.27
in general payments reported to CMS, 2019-2025
49 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,745 · 2020: $1,041 · 2021: $761 · 2022: $698 · 2023: $901 · 2024: $674 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,472.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,155.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $773.84 | 2019-2025 | Repatha, Evenity |
| Abbott Laboratories | $657.66 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $501.35 | 2019-2025 | Farxiga |
| Dexcom, INC. | $408.20 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $381.42 | 2019-2023 | Synthroid |
| Sanofi-Aventis U.S. LLC | $354.35 | 2019-2025 | |
| Insulet Corporation | $311.56 | 2019-2024 | Omnipod |
| Radius Health, INC. | $206.49 | 2020-2025 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $202.58 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $182.71 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.85 | 2019-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $163.19 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $126.52 | 2021-2023 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $124.78 | 2019-2023 | Korlym |
| Amarin Pharma, INC. | $120.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $102.79 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $82.49 | 2019-2025 | Strensiq |
| Nalpropion Pharmaceuticals LLC | $79.09 | 2019 | |
| Recordati_rare_diseases_inc. | $69.23 | 2023-2024 | Signifor Lar, Isturisa |
| Ibsa Pharma INC. | $68.42 | 2019 | |
| Currax Pharmaceuticals LLC | $54.88 | 2020-2021 | |
| Antares Pharma, INC. | $54.79 | 2020-2025 | Xyosted |
| Medtronic, INC. | $54.74 | 2024 | Intellis Adaptivestim, Minimed 780g |
| Medtronic Minimed, INC. | $51.21 | 2019-2020 | |
| Zealand Pharma US, INC. | $50.56 | 2021-2022 | |
| Mannkind Corporation | $46.28 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $46.16 | 2019 | |
| Halozyme INC | $43.06 | 2023 | |
| Beta Bionics, INC. | $40.60 | 2024 | Ilet Bionic Pancreas |
| Madrigal Pharmaceuticals | $39.35 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $38.37 | 2022-2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $31.09 | 2021-2023 | Nexletol |
| Horizon Therapeutics Plc | $27.18 | 2019 | |
| Alvogen INC | $26.42 | 2022 | |
| Pfizer INC. | $26.33 | 2019-2021 | |
| Shire North American Group INC | $25.60 | 2019 | |
| Amneal Pharmaceuticals LLC | $23.95 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.64 | 2019 | |
| Lifescan, INC. | $23.37 | 2020 | |
| Valeritas, INC. | $21.74 | 2019 | |
| Cequr Corporation | $20.13 | 2022-2024 | Cequr Simplicity |
| Eisai INC. | $19.29 | 2019 | |
| Kyowa Kirin, INC. | $18.90 | 2024 | |
| Glaxosmithkline, LLC. | $18.57 | 2025 | Shingrix, Arexvy |
| Verity Pharmaceuticals INC. | $18.39 | 2025 | Tlando |
| Acella Pharmaceuticals, LLC | $14.03 | 2023 | NP Thyroid 60 |
| Arbor Pharmaceuticals, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.